|1.||Li, Ying: 1 article (07/2015)|
|2.||Chai, Hongyan: 1 article (07/2015)|
|3.||Chen, Xuewei: 1 article (07/2015)|
|4.||Qin, Tian: 1 article (07/2015)|
|5.||Yue, Jiang: 1 article (07/2015)|
|6.||Tang, Tian: 1 article (07/2015)|
|7.||Wang, Chenlong: 1 article (07/2015)|
|8.||Yang, Jing: 1 article (07/2015)|
|9.||Zhang, Xiaoyan: 1 article (07/2015)|
|10.||Zhang, Jing: 1 article (07/2015)|
|1.||Sleep Initiation and Maintenance Disorders (Insomnia)
|2.||Schizophrenia (Dementia Praecox)
09/01/2010 - "Butaclamol is an antipsychotic drug used in the treatment of schizophrenia. "
01/01/1978 - "Butaclamol in the treatment of schizophrenia. "
11/01/1975 - "[Butaclamol in acute schizophrenia]."
01/01/2002 - "Competition experiments were performed in order to examine the pharmacological profile of [(3)H]spiperone binding, and revealed that: (i) displacement of [(3)H]spiperone binding by clozapine and mianserin was significantly reduced in the schizophrenia group as compared to the control group (-26% and -16% respectively); (ii) the order of displacement potency of the drugs tested was: haloperidol>mianserin>butaclamol approximately risperidone>clozapine>2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene. "
07/01/1978 - "Either of two DA receptor antagonists, haloperidol (0.04--7.0 microgram) or d-butaclamol (0.48--1.47 microgram), when given in a sufficient dose, effectively delayed the onset of the DA-hypothermia and reduced its absolute magnitude; however, the NE-induced decline in the cat's temperature was unaffected by DA receptor blockade. "
04/30/1975 - "In the dose range where the aforementioned effects were observed AY-23,028 did not antagonize either the tetrabenazine-induced ptosis or the tremorine syndrome and did not cause either hypothermia or ataxia. "
|5.||Ganglion Cysts (Ganglion)
01/06/1980 - "SQ10,631 also slows the endogenous decay of PTP in some preparations which exhibit an unusually fast PTP decay rate, suggesting a naturally occurring source of serotonin within the ganglion capable of affecting the rate constant of PTP decay; (4) (+)-butaclamol, a dopamine antagonist, blocks the effect of dopamine on the rate constant of PTP decay, whereas (-)-butaclamol has little effect. "
|6.||Dopamine Receptors (Dopamine Receptor)
|8.||Risperidone (Risperdal Consta)